Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)

Launched by BAYER · Jan 29, 2020

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with a qualifying oral OAC dispensed during the study period
• • A primary diagnosis indicative of atrial fibrillation during the baseline period
• Exclusion Criteria:
• • Age \< 18 years at index date
• • Died on index date
• • A diagnosis of valvular disease, pregnancy, transient cause of atrial fibrillation or venous thromboembolism in the baseline period or on the index date
• • Hip or knee replacement surgery in the 60 days prior to or on the index date
• • A dispensed prescription of heparin or fondaparinux in the 60 days prior to or on the index date
• • A diagnosis of end-stage kidney disease or renal replacement therapy in the baseline period or on the index date
• • More than one dispensed OAC (any dose of rivaroxaban, apixaban, dabigatran, edoxaban, or warfarin) on the index date
• • A dispensed prescription of an OAC (any dose of rivaroxaban, apixaban, dabigatran, edoxaban, or warfarin) during the baseline period